文献速递MDS 与骨髓增殖性肿瘤

下一代JAK抑制剂治疗骨髓增殖性肿瘤

Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.
PubMed 文献 · Blood · 2026-01-01

该综述讨论下一代JAK抑制剂治疗骨髓增殖性肿瘤(MPN)的进展,包括II型抑制及靶向JAK2 V617F假激酶域的抑制剂。理想抑制剂应靶向持续激活的JAK2并根除克隆或诱导深度分子缓解,同时保留野生型JAK2。文章还讨论临床试验终点与生物标志物。

要点

  • 已批准JAK抑制剂多靶向JAK2激酶域(I型),新型抑制剂可II型抑制或靶向假激酶域。
  • JAK2 V617F是MPN最常见突变,下一代抑制剂可能偏好或特异靶向该突变体。
  • 理想抑制剂应清除克隆或诱导深度分子缓解,同时保留野生型JAK2以维持造血和免疫。

核心结论

  • 下一代JAK抑制剂通过II型抑制或靶向JAK2 V617F假激酶域,有望实现优于传统药物的克隆清除或深度分子缓解。

研究设计与样本

  • 综述文章,讨论已进入临床试验的新型JAK抑制剂的作用机制、临床试验设计终点及潜在生物标志物。

主要发现

  • 已批准JAK抑制剂一般靶向JAK2激酶域,部分也靶向JAK1激酶域(I型抑制)。
  • 新型抑制剂可II型抑制激酶域(非活性状态)或靶向假激酶域,对JAK2 V617F突变体有潜在偏好或特异性。
  • JAK2 V617F是MPN中最 prevalent 的突变。

临床怎么用

  • 下一代JAK抑制剂旨在靶向MPN中持续激活的JAK2,同时保留野生型JAK2以维持正常造血和免疫。
  • 临床试验设计需关注主要和次要/探索性终点,并探索预测疗效的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Janus kinase (JAK) inhibitors have changed the treatment landscape of myeloproliferative neoplasms (MPNs), graft-versus-host disease, and several autoimmune conditions. Although approved JAK inhibitors generally target the JAK2 kinase domain, and several also target the JAK1 kinase domain in active form (type I inhibition), new inhibitors that either exhibit a type II mechanism of inhibition of the kinase domain in an inactive state or that target the pseudokinase domain with potential preference or specificity for the JAK2 V617F mutant have progressed to clinical trials. This is the most prevalent mutation in MPNs. An ideal inhibitor would target persistently activated JAK2 in MPNs, eradicate the clone or induce deep molecular remission in addition to clinical and hematologic remission, and spare wild-type JAK2 that is critical for hematopoiesis and immune response. We discuss perspectives of these and other modes of JAK inhibition, as well as primary and secondary/exploratory study end points in clinical trial design, along with potential biomarker correlates to evaluate the potential efficacy of next-generation vs conventional JAK inhibitors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Constantinescu SN, Vainchenker W, Pecquet C, et al. Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms. Blood. 2026. PMID: 41511882. doi:10.1182/blood.2025028645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。